All Posts

Researchers from the National University of Singapore and University of British Columbia have created a free online tool called the Risk of Exacerbation in Severe Asthma (RESA) e-tool to help clinicians estimate a person’s likelihood of having a serious asthma flare-up over the next 12 months. The work was recently published in The Journal of Allergy and Clinical Immunology: In Practice, entitled “Development and Validation of the Risk of Exacerbation in Severe Asthma (RESA)

Greek patients with severe asthma were found to have a notably lower asthma exacerbation rate compared with patients globally, while long-term oral corticosteroid (LTOCS) use, and importantly evidence of steroid-related disease, was substantially lower in Greece compared with Southern Europe and global rates. Differences in severe asthma characteristics, treatment patterns, and disease control between Greece, Southern Europe, and the global population have been identified in

On World Asthma Day 2026, we’re raising awareness of asthma- a condition affecting over 400 million people worldwide - and reflecting on the urgent need to rethink how we identify and manage its most serious forms.   Severe asthma continues to place a significant burden on patients and healthcare systems globally. At Optimum Patient Care (OPC), we’re proud to lead the International Severe Asthma Registry (ISAR), a collaborative global platform advancing real-world research

Pathways that predict severe asthma attacks (exacerbations) were found to be similar, with matching strength of prediction, in both clinical trials (Randomised Controlled Trials, RCTs) and real-world data (RWD) settings in the new International Severe Asthma Registry (ISAR) study “Interactive Pathways of Key Prognostic Factors in Severe Asthma: A Bayesian Network Comparison of Clinical Trials & Real-World Data”. Recently published in CHEST, this study performed a novel Bayesi

Long-term oral corticosteroid (LTOCS) use has been found to be lower in Mexican patients than globally and may be associated with impact to critical health outcomes, with potentially oral corticosteroid-related diseases found to be less common in Mexican patients. These findings are reported in the real-world study, “ Severe asthma patients’ characteristics in Mexico versus International Severe Asthma Registry (ISAR) Global ” , recently published in Current Allergy and Asthma

Expanding Global Collaboration in Severe Asthma: Highlights from the ISAR Industry Symposium On 27 September 2025, the International Severe Asthma Registry (ISAR) hosted its first industry-wide symposium, welcoming representatives from multiple countries, leading pharmaceutical companies, and research organisations. This milestone event marked ISAR’s transition from a single industry funded initiative to a truly global, multi-partner collaboration. Driving Impact Through Data

The real-world study, “ Response to biologics along a gradient of T2 involvement in patients with severe asthma: a data-driven biomarker clustering approach ”, was recently published in The Journal of Allergy and Clinical Immunology: In Practice . Five biomarker clusters along a gradient of T2 involvement were identified using a data-driven approach instead of the pre-defined thresholds used in prior studies. Biologic use (Anti-IgE, Anti-IL5/5R and Anti-IL4Rα) was associated

A novel Bayesian Network analysis on the International Severe Asthma Registry (ISAR) has identified key clinical and biological pathways...

The real-world study, “ Biomarker profile and disease burden associated with intermittent and long-term oral corticosteroid use in...

Drawing on data from over 5,600 severe asthma patients across real-world specialist and primary care settings in 22 countries, the SOLAR...

New real-world insights from the International Severe Asthma Registry (ISAR), spanning data from over 25 countries, have been featured in...

The real-world SOLAR II study shows that biologic initiators had 18% lower risk of developing any oral corticosteroid (OCS)-related...

A recently published study in Pragmatic and Observational Research, “Real-world biologic use patterns in severe asthma, 2015–2021: the...

The EVEREST study published in the Journal of Asthma and Allergy, “Disease Burden and Access to Biologic Therapy in Patients with Severe...

The International Severe Asthma Registry (ISAR) ’s new study, “ Exploring definitions and predictors of response to biologics for severe...

We are excited to share groundbreaking findings on remission as a therapeutic target in " Exploring definitions and predictors of severe...

Singapore, [25 June 2024] – A new analysis of data from the International Severe Asthma Registry (ISAR) has revealed a spectrum of...

A new real-world research study from ISAR, the International Severe Asthma Registry, reveals the strength of the asthma tests...

The International Severe Asthma Registry is a global collaborative initiative to gather anonymous, longitudinal, real-life data for...

ISAR ’s new publication "Association between T2-related co-morbidities and effectiveness of biologics in severe asthma” to the highly...